영어 모의고사 (자동 편성)

Two drivers, equally distracted by their phones, run a red light in exactly the same careless manner. By pure chance, a child happens to be crossing the street in front of one driver but not the other; the first driver kills the child, while the second driver drives through safely and never even notices the danger. Although both drivers behaved ①identically and made exactly the same reckless choice, society judges them very differently: one faces criminal charges and lifelong guilt, while the other receives, at most, a minor traffic ticket. Philosophers call this troubling ②asymmetry moral luck, since factors entirely outside a person's control end up determining how severely we judge their moral character. If moral responsibility is supposed to ③depend heavily on luck and circumstance rather than on what a person chooses and intends, this outcome seems deeply unfair, yet few people are willing to excuse the unlucky driver as if nothing worse had happened. Moral luck suggests that our everyday judgments rest on a foundation far ④shakier than we usually like to admit, a fact many find genuinely ⑤unsettling.

The immune system produces an almost limitless variety of antibodies, each shaped to latch onto one particular molecular target with remarkable ①specificity. Monoclonal antibody drugs harness this natural precision by cloning a single antibody-producing cell in the laboratory, generating an army of identical antibodies built to recognize one target, such as a protein on a cancer cell or a molecule driving an autoimmune disease. Because the antibody binds only to its intended target, these drugs tend to spare healthy tissue far more ②effectively than traditional chemotherapy, which attacks any rapidly dividing cell regardless of whether it is cancerous. Manufacturing monoclonal antibodies remains far more ③complicated than producing a conventional small-molecule pill, since living cells must be cultivated in carefully controlled bioreactors for weeks before the antibody can be purified and prepared for use. This complexity keeps monoclonal antibody treatments considerably more ④expensive than most conventional drugs, a cost that continues to ⑤resolve debates over pricing and access.

Imagine rewriting a bacterium's code the way a programmer edits a line of software, and much of what synthetic biology ①promises begins to make sense. Researchers in this field assemble standardized genetic parts into circuits that can be inserted into a cell, instructing it to perform a task that no natural organism would ②carry out. Because these circuits are built from interchangeable parts rather than designed from scratch each time, a circuit tested in one lab can often be reused, with ③minor adjustments, in an entirely different application. Critics note that biological systems ④always behave as predictably as electronic circuits, since a gene inserted into a new cell can interact with existing pathways in unexpected ways, occasionally producing results no engineer intended. Even so, as the catalog of standardized parts keeps expanding, engineers are gaining ⑤confidence to design increasingly complex systems.

For patients born with a single faulty gene, the disease has traditionally been treated ①indirectly, managing symptoms for a lifetime rather than addressing the genetic error itself. Gene therapy attempts something more ambitious: delivering a corrected copy of the gene directly into a patient's cells, often using a ②reinforced virus stripped of its ability to cause illness as a delivery vehicle. Once inside the nucleus, the corrected gene can begin producing the protein the patient's body had always lacked, in some cases ③reversing symptoms that medication alone had never been able to touch. Early trials were haunted by serious ④setbacks, including cases in which the delivery virus triggered a dangerous immune reaction. Refined delivery methods have since made the treatment considerably ⑤safer, and regulators in several countries have now approved gene therapies for a small but growing number of rare inherited disorders.

It would be comforting to believe that anything sufficiently large or obvious appearing within our field of vision will automatically capture our attention, yet decades of research into inattentional blindness suggest otherwise. When people are absorbed in a demanding task, such as counting how many times a ball is passed between players, they frequently fail to notice an unexpected and conspicuous event unfolding in plain sight, even something as unlikely as a person in a costume walking through the scene. This failure does not stem from a defect in the eyes, which register the stimulus perfectly well, but from the fact that _______________. Policymakers ought to take this finding more seriously than they currently do, because it implies that simply placing a warning sign within someone's visual range offers no guarantee that it will be consciously registered. Designing safer environments, therefore, requires accounting for the limits of attention itself, not merely assuming that visibility alone ensures awareness.

Two patients diagnosed with the same disease and prescribed the same medication can respond in strikingly different ways, one recovering quickly while the other experiences little benefit or even harmful side effects. (A) This approach has proven especially valuable in cancer treatment, where tumors from two patients with the same diagnosis may carry entirely different genetic mutations that respond to entirely different drugs, though widespread adoption still faces real obstacles, since genetic sequencing remains expensive in many regions. (B) By sequencing a patient's DNA before treatment begins, doctors can increasingly predict which medication is likely to work best and at what dose, replacing a strategy once described as one-size-fits-all with something closer to a tailored fit. (C) Precision medicine starts from the observation that this variation often traces back to differences buried in each patient's genome, differences that determine how efficiently a body absorbs, breaks down, or responds to a given drug.

The human gut hosts trillions of microorganisms whose combined genetic material outnumbers that of the human genome itself many times over. (A) A microbiome disrupted by antibiotics, poor diet, or chronic stress can leave the gut lining more permeable than it should be, allowing substances to leak into the bloodstream that would normally stay contained. (B) Once dismissed as passive hitchhikers, these bacteria are now understood to actively shape digestion, regulate immune responses, and even influence the production of chemicals that affect mood and behavior. (C) Researchers studying this connection have found that transplanting gut bacteria from a healthy donor into a patient can relieve symptoms of certain digestive disorders, though the microbiome varies enormously between individuals, so a treatment that helps one person's gut may do little for someone else's.

A plastic bag that fully decomposes within months rather than lingering for centuries sounds almost too convenient to be real, yet certain bioplastics on the market do exactly that under the right conditions. (A) Not every bioplastic biodegrades quickly, however, and some marketed as eco-friendly break down only in industrial composting facilities that reach conditions rarely found in a backyard compost heap or the open ocean. (B) Unlike conventional plastic, derived almost entirely from petroleum, many bioplastics are synthesized from renewable feedstocks such as corn starch or sugarcane, sometimes with the help of bacteria engineered to produce plastic-like polymers as a byproduct of their metabolism. (C) Critics point out that growing crops for bioplastic production can compete with food crops for farmland and water, which is why researchers are now exploring bioplastics made from agricultural waste and algae instead of dedicated crops.

That freedom, however, comes with an important caveat about what these structures can and cannot tell us. A cluster of neurons smaller than a pea can now spontaneously organize itself into layered structures that mimic, in miniature, the architecture of a developing human brain. ( ① ) Grown from stem cells coaxed to follow the same developmental cues that guide an embryo, these brain organoids have begun firing electrical signals in patterns that faintly resemble the activity recorded in an infant's brain. ( ② ) For researchers studying disorders such as autism or schizophrenia, this offers something long unavailable: a living model of human brain development that can be observed and manipulated directly. ( ③ ) This can happen without ever touching an actual patient. ( ④ ) Because organoids lack sensory organs, a body, or any connection to the outside world, most neuroscientists argue that the structures cannot generate anything resembling subjective experience, however brain-like their electrical activity may appear. ( ⑤ ) Even so, the pace at which these organoids are growing more complex has convinced some ethicists that the field would benefit from establishing clear boundaries now, before the science outruns the conversation about what it means.

The practical consequence of this precision has been a dramatic acceleration in the pace of genetic research itself. Bacteria have been cutting up invading viral DNA for billions of years, long before any scientist thought to borrow the trick for use in a laboratory. ( ① ) The CRISPR-Cas9 system, as it is now known, relies on a short guide RNA that matches a specific DNA sequence, leading a scissor-like enzyme called Cas9 directly to that exact location in the genome. ( ② ) Once Cas9 arrives at the target site, it slices both strands of the DNA helix, and the cell's own repair machinery rushes in to mend the cut, often introducing a small change in the process. ( ③ ) By supplying the cell with a template during this repair step, scientists can direct that machinery to insert a specific new sequence. ( ④ ) This goes well beyond merely disabling the original gene. ( ⑤ ) What once required years of painstaking work to alter a single gene can now, with a properly designed guide RNA, be accomplished within days.